A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma Meeting Abstract
| Authors: | Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; Agresta, S.; Reilly, S.; Patriquin, C. M.; Hickman, D.; Corrigan, D.; Granlund, L.; Hentemann, M.; Piel, J.; Martin, P.; Mehmi, I. |
| Abstract Title: | A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S677 |
| End Page: | S678 |
| Language: | English |
| ACCESSION: | WOS:001087480201459 |
| DOI: | 10.1016/j.annonc.2023.09.2262 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1128P -- Source: Wos |
